Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable
hematological malignancy that affects the myeloid cell progenies and challenges patients of …

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the
second most common form of acute leukemia in children. Despite this, very little …

Background Several important treatment and supportive care strategies have been
implemented over the past 4 decades in the management of acute myeloid leukemia (AML) …

Dysregulation of cancer cell metabolism contributes to abnormal cell growth, the biological
end point of cancer. We review here numerous affected oncogenes and metabolic pathways …

Acute myeloid leukemia (AML) is a heterogenous and complex disease characterized by
rapid cellular proliferation, an aggressive clinical course, and generally high mortality. While …

Despite impressive efforts invested in epigenetic research in the last 50 years, clinical
applications are still lacking. Only a few university hospital centers currently use epigenetic …

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that
has a poor prognosis. Recent advances in genomics and molecular biology have led to a …

Metabolic rewiring and cellular reprogramming are trademarks of neoplastic initiation and
progression in acute myeloid leukemia (AML). Metabolic alteration in leukemic cells is often …

Isocitrate dehydrogenase (IDH) is a key metabolic enzyme catalyzing the interconversion of
isocitrate to α-ketoglutarate (α-KG). Mutations in IDH lead to loss of normal enzymatic activity …

Bevacizumab is included in an increasing number of clinical trials. To find biomarkers to
predict and monitor treatment response, cancer and angiogenesis relevant mutations in …